Date: 2014-02-01
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: AstraZeneca
Product: MEDI1814
Action
mechanism: monoclonal antibody.
Disease: Alzheimer\'s disease
Therapeutic area: Neurodegenerative diseases
Country: USA
Trial
details: The purpose of this randomised double-blind placebo-controlled, single and multiple ascending dose study is to assess the safety, drug levels and effects on the body of 1 or 3 injections of MEDI1814, in people with mild to moderate Alzhiemer\'s Disease or healthy elderly people. (NCT02036645)
Latest
news:
